A Phase 3 interventional study of Alpelisib and Olaparib in Ovarian Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 93 sites in 26 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D,…PubMed 40700681 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, and was the 49th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 358 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 97 across the 69 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
23 studies in Ovarian Neoplasms by Novartis: none open now, 1 under way, none of them phase 3. Of 22 finished, 8 (36%) have results posted.
Among the 23 studies in Ovarian Neoplasms by Novartis, this one is the 4th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 3, and was the 20th registered.
Novartis’s Ovarian Neoplasms studies by the year they started, since 1997.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among Novartis’s 23 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory, germline BRCA non-mutated (gBRCAnm) high-grade serous ovarian cancer (HGSOC), with progression-free survival (PFS) as the primary efficacy endpoint.
This study enrolled adult women with platinum-resistant or platinum-refractory high-grade serous ovarian cancer (HGSOC) who did not have a detected germline BRCA mutation. In this open-label, active-controlled study, participants were randomized 1:1 to receive either alpelisib plus olaparib or single-agent cytotoxic chemotherapy (paclitaxel or pegylated liposomal doxorubicin [PLD]).
The study comprised four phases: a 28-day pre-treatment phase, a randomized treatment phase, a post-treatment follow-up phase for safety and efficacy assessments, and a post-treatment survival follow-up phase. Participants continued study treatment until disease progression, unacceptable toxicity, death, or discontinuation for any other reason.
Because the study did not achieve its primary objective, Protocol Amendment 03 removed the post-treatment survival follow-up phase. Subsequently, Protocol Amendment 04 modified the study design by removing the efficacy follow-up phase.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Key Inclusion criteria:
Key Exclusion criteria:
Other inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alpelisib (200 mg once daily after food) and Olaparib (200 mg twice daily) were both administered orally on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
Drug: Alpelisib · Drug: Olaparib
Paclitaxel (80 mg/m²) was administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle, or Pegylated liposomal doxorubicin (40-50 mg/m² at physician discretion) was administered as an intravenous infusion once every 28 days starting on Cycle 1 Day 1.
Drug: Paclitaxel · Drug: Pegylated liposomal doxorubicin (PLD)
Alpelisib was administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
Also known as: BYL719
Olaparib was administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
Paclitaxel (80 mg/m²) was administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle.
Pegylated liposomal doxorubicin (40-50 mg/m² at physician discretion) was administered as an intravenous infusion once every 28 days starting on Cycle 1 Day 1.
Progression Free Survival (PFS) Based on Blinded Independent Review Committee (BIRC) Assessment Using RECIST 1.1 Criteria
Progression-free survival (PFS) was defined as the time from randomization to the first documented disease progression or death from any cause, as determined by blinded independent review committee (BIRC) assessment. Participants without an event were censored at the date of their last adequate tumor assessment. Clinical deterioration without objective radiologic evidence was not considered disease progression in the primary efficacy analysis. Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including baseline), with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of non-target lesions.
Time frame: From randomization until the date of the first documented progression or death due to any cause, whichever comes first, assessed up to approximately 21 months
Overall Survival
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If a participant was not known to have died, OS was censored at the latest date the participant was known to be alive (on or before the cut-off date), i.e., the last known date the participant was alive (last contact date).
Time frame: From randomization until death, assessed up to approximately 44 months
Overall Response Rate (ORR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 Criteria
Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) by blinded independent review committee (BIRC) assessment as per RECIST 1.1 criteria: * CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. * PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to approximately 21 months
Clinical Benefit Rate (CBR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1
Clinical benefit rate (CBR) with confirmed response was defined as the percentage of participants whose best overall response was a confirmed CR or PR, or stable disease (SD) maintained for at least 24 weeks. CR, PR, and SD were determined by BIRC according to RECIST 1.1 criteria.
Time frame: Up to approximately 21 months
Time to Response (TTR) Based on BIRC Assessment and According to RECIST 1.1
Time to response (TTR) was defined as the interval from randomization to the first documented occurrence of either complete response (CR) or partial response (PR), which was subsequently confirmed (using the date of initial response, not the confirmation date). CR and PR were determined based on tumor response data assessed by BIRC according to RECIST 1.1 criteria.
Time frame: From the date of randomization to the first documented response, assessed through Month 12
Duration of Response (DOR) With Confirmed Response Based on BIRC Assessment and According to RECIST 1.1
Duration of response (DOR) with confirmed response was calculated only for participants whose best overall response was a confirmed complete response (CR) or confirmed partial response (PR), based on tumor response data assessed by BIRC according to RECIST 1.1. The start date was the date of the first documented CR or PR (i.e., the initial response date, not the confirmation date), and the end date was the date of first documented disease progression or death due to underlying cancer. Participants without progression or cancer-related death were censored at the date of their last adequate tumor assessment.
Time frame: From first documented response to first documented progression or death, assessed up to approximately 21 months
Time to Definitive Deterioration of the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Performance status (PS) was evaluated using the ECOG scale, which comprises six grades (0 to 5), where 0 represents fully active and 5 represents death. Time to definitive deterioration in ECOG PS was defined as the interval from randomization to the date when ECOG PS worsened by at least one category from baseline and remained worsened. Deterioration was considered definitive if there was no subsequent improvement to the baseline category or better. Participants were censored if no definitive deterioration occurred before the earlier of: (i) the analysis cut-off date or (ii) initiation of a new anti-neoplastic therapy. The censoring date was the date of the last PS assessment prior to the cut-off or start of new therapy.
Time frame: Up to approximately 18 months
Number of Participants With Dose Interruptions and Dose Reductions
The number of participants with dose reductions/interruptions was assessed and summarized by study treatment.
Time frame: From randomization until end of treatment, assessed up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD)
Dose Intensity for Alpelisib and Olaparib
Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.
Time frame: From randomization until end of treatment, assessed up to approximately 39 months
Dose Intensity for Paclitaxel
Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.
Time frame: From randomization until end of treatment, assessed up to approximately 45 months
Dose Intensity for Pegylated Liposomal Doxorubicin
Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.
Time frame: From randomization until end of treatment, assessed up to approximately 23 months
Area Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and Olaparib
Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUCtau was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Area Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of Alpelisib and Olaparib
Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUClast was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Maximum Concentration (Cmax) of Alpelisib and Olaparib
Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. Cmax was listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Time to Reach Maximum Concentration (Tmax) of Alpelisib and Olaparib
Venous blood samples were collected to characterize the pharmacokinetics (PK) of alpelisib when administered in combination with olaparib. Time to maximum observed plasma concentration (Tmax) was calculated using actual sample collection times rather than nominal scheduled sampling times and was summarized using descriptive statistics.
Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Time to Definitive Deterioration by 10% in FACT-O Trial Outcomes Index (TOI) Score
The Functional Assessment of Cancer Therapy-Ovarian (FACT O) is a validated instrument that evaluates quality of life in patients with ovarian cancer. The Trial Outcome Index (TOI) of the FACT-O combines Physical Well Being (PWB), Functional Well Being (FWB), and the Ovarian Cancer Subscale (OCS), and its scores range from 0 to 100, with higher scores indicating better quality of life and physical/functional status. Time to definitive deterioration by 10% in FACT O TOI is defined as the time from randomization to the first occurrence of at least a 10% worsening from baseline with no subsequent improvement above this threshold, or death. Participants without an event before analysis cut off or before starting another anticancer therapy were censored at their last adequate assessment. Time to deterioration was estimated using the Kaplan-Meier method.
Time frame: Baseline, up to 15 months
The study was conducted globally across 94 centers in 26 countries.
| Milestone | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Started | 180 | 178 |
| Safety set (saf) | 180 | 164 |
| Completed | 0 | 0 |
| Not completed | 180 | 178 |
| Withdrew: Randomized, not treated | 0 | 14 |
| Withdrew: Progressive disease (pd) per local blinded independent review committee (birc) | 75 | 70 |
| Withdrew: Physician decision | 22 | 30 |
| Withdrew: Progressive disease (pd) per local investigator | 20 | 30 |
| Withdrew: Adverse event | 27 | 10 |
| Withdrew: Subject decision | 24 | 11 |
| Withdrew: Death | 11 | 9 |
| Withdrew: No pd per birc or local investigator recorded before end of treatment (eot) with reason pd | 1 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
Progression-free survival (PFS) was defined as the time from randomization to the first documented disease progression or death from any cause, as determined by blinded independent review committee (BIRC) assessment. Participants without an event were censored at the date of their last adequate tumor assessment. Clinical deterioration without objective radiologic evidence was not considered disease progression in the primary efficacy analysis. Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including baseline), with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of non-target lesions.
| Months | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Progression Free Survival (PFS) Based on Blinded Independent Review Committee (BIRC) Assessment Using RECIST 1.1 Criteria | 3.6 (3.35 to 4.27) | 3.9 (3.68 to 5.36) |
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If a participant was not known to have died, OS was censored at the latest date the participant was known to be alive (on or before the cut-off date), i.e., the last known date the participant was alive (last contact date).
| Months | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Overall Survival | 12.45 (8.44 to 15.01) | 11.99 (10.18 to 14.19) |
Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) by blinded independent review committee (BIRC) assessment as per RECIST 1.1 criteria: * CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. * PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
| Percentage of participants | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Overall Response Rate (ORR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 Criteria | 15.6 (10.6 to 21.7) | 13.5 (8.8 to 19.4) |
Clinical benefit rate (CBR) with confirmed response was defined as the percentage of participants whose best overall response was a confirmed CR or PR, or stable disease (SD) maintained for at least 24 weeks. CR, PR, and SD were determined by BIRC according to RECIST 1.1 criteria.
| Percentage of participants | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Clinical Benefit Rate (CBR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 | 21.1 (15.4 to 27.8) | 19.1 (13.6 to 25.7) |
Time to response (TTR) was defined as the interval from randomization to the first documented occurrence of either complete response (CR) or partial response (PR), which was subsequently confirmed (using the date of initial response, not the confirmation date). CR and PR were determined based on tumor response data assessed by BIRC according to RECIST 1.1 criteria.
| Months | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Time to Response (TTR) Based on BIRC Assessment and According to RECIST 1.1 | NA (NA to NA) | NA (NA to NA) |
Duration of response (DOR) with confirmed response was calculated only for participants whose best overall response was a confirmed complete response (CR) or confirmed partial response (PR), based on tumor response data assessed by BIRC according to RECIST 1.1. The start date was the date of the first documented CR or PR (i.e., the initial response date, not the confirmation date), and the end date was the date of first documented disease progression or death due to underlying cancer. Participants without progression or cancer-related death were censored at the date of their last adequate tumor assessment.
| Months | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Duration of Response (DOR) With Confirmed Response Based on BIRC Assessment and According to RECIST 1.1 | 7.36 (4.96 to 12.94) | 5.5 (3.78 to NA) |
Performance status (PS) was evaluated using the ECOG scale, which comprises six grades (0 to 5), where 0 represents fully active and 5 represents death. Time to definitive deterioration in ECOG PS was defined as the interval from randomization to the date when ECOG PS worsened by at least one category from baseline and remained worsened. Deterioration was considered definitive if there was no subsequent improvement to the baseline category or better. Participants were censored if no definitive deterioration occurred before the earlier of: (i) the analysis cut-off date or (ii) initiation of a new anti-neoplastic therapy. The censoring date was the date of the last PS assessment prior to the cut-off or start of new therapy.
| Months | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Time to Definitive Deterioration of the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) | 6.0 (3.98 to 8.31) | 7.4 (4.24 to NA) |
The number of participants with dose reductions/interruptions was assessed and summarized by study treatment.
| Participants | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Alpelisib — Participants with no dose reduction and/or interruption | 53 | — |
| Alpelisib — Participants with at least one dose reduction and/or interruption | 127 | — |
| Olaparib — Participants with no dose reduction and/or interruption | 63 | — |
| Olaparib — Participants with at least one dose reduction and/or interruption | 117 | — |
| Paclitaxel — Participants with no dose reduction and/or interruption | — | 33 |
| Paclitaxel — Participants with at least one dose reduction and/or interruption | — | 37 |
| Pegylated liposomal Doxorubicin (PLD) — Participants with no dose reduction and/or interruption | — | 81 |
| Pegylated liposomal Doxorubicin (PLD) — Participants with at least one dose reduction and/or interruption | — | 13 |
Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.
| mg/day | Alpelisib 200mg + Olaparib 200mg |
|---|---|
| Alpelisib | 181.2 (62.8 to 201.8) |
| Olaparib | 383.7 (103.4 to 400) |
Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.
| mg/m^2/7 days | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|
| Dose Intensity for Paclitaxel | 71.1 (35.4 to 84) |
Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.
| mg/m^2/28-days | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|
| Dose Intensity for Pegylated Liposomal Doxorubicin | 40 (10 to 50.5) |
Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUCtau was listed and summarized using descriptive statistics.
| hr*ng/mL | Alpelisib 200mg + Olaparib 200mg |
|---|---|
| Alpelisib | 22194.3 ± 51.1 |
| Olaparib | 39939.1 ± 59.1 |
Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUClast was listed and summarized using descriptive statistics.
| hr*ng/mL | Alpelisib 200mg + Olaparib 200mg |
|---|---|
| Alpelisib | 19806.8 ± 63.8 |
| Olaparib | 2783.4 ± 82.2 |
Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. Cmax was listed and summarized using descriptive statistics.
| ng/mL | Alpelisib 200mg + Olaparib 200mg |
|---|---|
| Alpelisib | 2029.3 ± 871.29 |
| Olaparib | 7313.2 ± 2429.27 |
Venous blood samples were collected to characterize the pharmacokinetics (PK) of alpelisib when administered in combination with olaparib. Time to maximum observed plasma concentration (Tmax) was calculated using actual sample collection times rather than nominal scheduled sampling times and was summarized using descriptive statistics.
| hour (hr) | Alpelisib 200mg + Olaparib 200mg |
|---|---|
| Alpelisib | 2.4 (0 to 8.2) |
| Olaparib | 2.0 (0 to 6.0) |
The Functional Assessment of Cancer Therapy-Ovarian (FACT O) is a validated instrument that evaluates quality of life in patients with ovarian cancer. The Trial Outcome Index (TOI) of the FACT-O combines Physical Well Being (PWB), Functional Well Being (FWB), and the Ovarian Cancer Subscale (OCS), and its scores range from 0 to 100, with higher scores indicating better quality of life and physical/functional status. Time to definitive deterioration by 10% in FACT O TOI is defined as the time from randomization to the first occurrence of at least a 10% worsening from baseline with no subsequent improvement above this threshold, or death. Participants without an event before analysis cut off or before starting another anticancer therapy were censored at their last adequate assessment. Time to deterioration was estimated using the Kaplan-Meier method.
| Months | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) |
|---|---|---|
| Time to Definitive Deterioration by 10% in FACT-O Trial Outcomes Index (TOI) Score | 3.7 (2.4 to 4.2) | 3.8 (2.1 to 11.1) |
Collected over Adverse events (AEs) were collected from the first dose of study treatment through 30 days after the last dose (on-treatment period), for up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD). Deaths occurring the post-treatment period were collected through study completion, including an additional follow-up period of approximately 14, 8, and 30 months, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpelisib 200mg + Olaparib 200mg (On-Treatment) | 27/180 (15%) | 98/180 (54.4%) | 176/180 (97.8%) |
| Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (On-Treatment) | 7/178 (3.9%) | 52/164 (31.7%) | 156/164 (95.1%) |
| Alpelisib 200mg + Olaparib 200mg (Post-Treatment) | 90/180 (50%) | — | — |
| Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (Post-Treatment) | 93/178 (52.2%) | — | — |
| Event | Alpelisib 200mg + Olaparib 200mg (On-Treatment) | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (On-Treatment) | Alpelisib 200mg + Olaparib 200mg (Post-Treatment) | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (Post-Treatment) |
|---|---|---|---|---|
| Malignant gastrointestinal obstructionGastrointestinal disorders | 8/180 | 13/164 | — | — |
| NauseaGastrointestinal disorders | 12/180 | 1/164 | — | — |
| AscitesGastrointestinal disorders | 6/180 | 10/164 | — | — |
| VomitingGastrointestinal disorders | 10/180 | 1/164 | — | — |
| HyperglycaemiaMetabolism and nutrition disorders | 9/180 | 0/164 | — | — |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 7/180 | 2/164 | — | — |
| PneumoniaInfections and infestations | 6/180 | 4/164 | — | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/180 | 2/164 | — | — |
| Intestinal obstructionGastrointestinal disorders | 1/180 | 5/164 | — | — |
| Acute kidney injuryRenal and urinary disorders | 5/180 | 0/164 | — | — |
| Event | Alpelisib 200mg + Olaparib 200mg (On-Treatment) | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (On-Treatment) | Alpelisib 200mg + Olaparib 200mg (Post-Treatment) | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (Post-Treatment) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 111/180 | 51/164 | — | — |
| HyperglycaemiaMetabolism and nutrition disorders | 91/180 | 6/164 | — | — |
| DiarrhoeaGastrointestinal disorders | 77/180 | 29/164 | — | — |
| VomitingGastrointestinal disorders | 74/180 | 33/164 | — | — |
| AnaemiaBlood and lymphatic system disorders | 68/180 | 60/164 | — | — |
| Decreased appetiteMetabolism and nutrition disorders | 62/180 | 27/164 | — | — |
| FatigueGeneral disorders | 52/180 | 31/164 | — | — |
| Abdominal painGastrointestinal disorders | 44/180 | 32/164 | — | — |
| ConstipationGastrointestinal disorders | 40/180 | 30/164 | — | — |
| AstheniaGeneral disorders | 35/180 | 36/164 | — | — |
| Age, Continuous(Years) | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) | Total |
|---|---|---|---|
| Mean | 60 ± 9.91 | 61 ± 9.52 | 60.5 ± 9.72 |
| Sex: Female, Male(Participants) | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) | Total |
|---|---|---|---|
| Female | 180 | 178 | 358 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 48 | 31 | 79 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 121 | 139 | 260 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 7 | 5 | 12 |
| Eastern Cooperative Oncology Group (ECOG) performance status (PS)(Participants) | Alpelisib 200mg + Olaparib 200mg | Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) | Total |
|---|---|---|---|
| Grade 0: Fully active, able to carry on all pre-disease performance without restriction. | 115 | 109 | 224 |
| Grade 1: Limited strenuous activity; ambulatory and able to do light or sedentary work. | 64 | 68 | 132 |
| Grade 2: Self-care capable, ambulatory; no work; active >50% of waking hours. | 1 | 0 | 1 |
| Grade 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. | 0 | 0 | 0 |
| Grade 4: Completely disabled; cannot carry on any self-care; totally confined to bed or chair. | 0 | 0 | 0 |
| Grade 5: Dead | 0 | 0 | 0 |
| Missing | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2021 to primary completion in Apr 2023, 20 months.
Results were first posted in Jun 2026, 3 years 1 month after primary completion. A results delay was requested in Apr 2024.
How these figures are worked out, and which studies are left out of them.
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D,…PubMed 40700681 ↗
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D,…PubMed 40700681 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alpelisib · Olaparib